Evidence map›Paper›PMID 37629024›Full record

ReviewInternational journal of molecular sciences2023

Liposome-Based Carriers for CRISPR Genome Editing.

Xing Yin, Romain Harmancey, David D McPherson, Hyunggun Kim, Shao-Ling Huang

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Nature Inspired Delivery Vehicles for CRISPR-Based Genome Editing.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Xing YinDivision of Cardiovascular Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.ORCID 0000-0003-3444-6687
Romain HarmanceyDivision of Cardiovascular Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
David D McPhersonDivision of Cardiovascular Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Hyunggun KimDepartment of Biomechatronic Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea.ORCID 0000-0001-9797-5872
Shao-Ling HuangDivision of Cardiovascular Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
The University of Texas Health Science Center at Houston · USSungkyunkwan University · KR

Funding

Echogenic Targeted Liposomes: Transfection/Drug DeliveryR01HL135092 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI David D McPherson · 2017 to 2026
$5.0M
Epigenetic Markers and Sustained Cytoprotection for Stroke TreatmentR42NS098918 · NINDS · ZYMO RESEARCH CORPORATION · PI Keith Booher, Shaoling Huang · 2021 to 2026
$4.4M
Epigenetic Markers and Sustained Cytoprotection for Stroke TreatmentR41NS098918 · NINDS · ZYMO RESEARCH CORPORATION · PI BOOHER, KEITH, GUO, WEI · 2017 to 2017
$225k
NIH HHS HL135092, McPhersonNIH HHS NS098918, Booker and HuangNINDS NIH HHS R41 NS098918NINDS NIH HHS R42 NS098918
6 · The paper itself

Abstract

The CRISPR-based genome editing technology, known as clustered regularly interspaced short palindromic repeats (CRISPR), has sparked renewed interest in gene therapy. This interest is accompanied by the development of single-guide RNAs (sgRNAs), which enable the introduction of desired genetic modifications at the targeted site when used alongside the CRISPR components. However, the efficient delivery of CRISPR/Cas remains a challenge. Successful gene editing relies on the development of a delivery strategy that can effectively deliver the CRISPR cargo to the target site. To overcome this obstacle, researchers have extensively explored non-viral, viral, and physical methods for targeted delivery of CRISPR/Cas9 and a guide RNA (gRNA) into cells and tissues. Among those methods, liposomes offer a promising approach to enhance the delivery of CRISPR/Cas and gRNA. Liposomes facilitate endosomal escape and leverage various stimuli such as light, pH, ultrasound, and environmental cues to provide both spatial and temporal control of cargo release. Thus, the combination of the CRISPR-based system with liposome delivery technology enables precise and efficient genetic modifications in cells and tissues. This approach has numerous applications in basic research, biotechnology, and therapeutic interventions. For instance, it can be employed to correct genetic mutations associated with inherited diseases and other disorders or to modify immune cells to enhance their disease-fighting capabilities. In summary, liposome-based CRISPR genome editing provides a valuable tool for achieving precise and efficient genetic modifications. This review discusses future directions and opportunities to further advance this rapidly evolving field.

Indexed as

Gene EditingLiposomesBiotechnologyCuesRNA, Guide, CRISPR-Cas SystemsLiposomesRNA, Guide, CRISPR-Cas SystemsCRISPR/Cas9gene deliverygene editinggRNAliposomesingle-guide RNA

Identifiers

PMID37629024
PMCPMC10454197
OpenAlexW4385877495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.